(Q43727179)

26 November 2017

title

Cost-effectiveness of transfusion of platelet components prepared with pathogen inactivation treatment in the United States (English)

1 reference

26 November 2017

main subject

United States of America

0 references

5

Maarten J Postma

1 reference

26 November 2017

Christopher E Bell

1

1 reference

26 November 2017

Marc F Botteman

2

1 reference

26 November 2017

Xin Gao

3

1 reference

26 November 2017

Joel L Weissfeld

4

1 reference

26 November 2017

Chris L Pashos

6

1 reference

26 November 2017

Darrell Triulzi

7

1 reference

26 November 2017

Ulf Staginnus

8

1 reference

26 November 2017

publication date

1 September 2003

1 reference

26 November 2017

published in

Clinical Therapeutics

1 reference

26 November 2017

volume

25

1 reference

26 November 2017

issue

9

1 reference

26 November 2017

page(s)

2464-2486

1 reference

Postoperative mortality after total hip arthroplasty. An analysis of deaths after two thousand seven hundred and thirty-six procedures.

26 November 2017

cites work

1 reference

12 December 2020

Hepatitis C virus transmission by a blood donation negative in nucleic acid amplification tests for viral RNA.

1 reference

12 December 2020

Life expectancy and cost utility after total hip replacement.

1 reference

12 December 2020

Human T-cell lymphotropic virus testing of blood donors in Norway: a cost-effect model

1 reference

12 December 2020

One thousand health-related quality-of-life estimates

1 reference

12 December 2020

Cost effectiveness of screening for hepatitis C virus in asymptomatic, average-risk adults.

1 reference

12 December 2020

A model of the health and economic impact of posttransfusion hepatitis C: application to cost-effectiveness analysis of further expansion of HCV screening protocols

1 reference

12 December 2020

Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C.

1 reference

12 December 2020

The cost-effectiveness of reducing donor exposures with single-donor versus pooled random-donor platelets.

1 reference

12 December 2020

Microorganisms strike back--infectious diseases during the last 50 years

1 reference

12 December 2020

Hepatitis C: natural history, diagnosis, and management.

1 reference

12 December 2020

[Long-term prognosis of chronic B and C viral hepatitis]

1 reference

12 December 2020

Safety and cost-effectiveness of solvent-detergent-treated plasma. In search of a zero-risk blood supply

1 reference

12 December 2020

Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C.

1 reference

12 December 2020

The Declining Risk of Post-Transfusion Hepatitis C Virus Infection

1 reference

12 December 2020

Costs, effects and C/E-ratios alongside a clinical trial.

1 reference

12 December 2020

Single-donor platelets reduce the risk of septic platelet transfusion reactions.

1 reference

12 December 2020

Cost-effectiveness of 6 and 12 months of interferon-alpha therapy for chronic hepatitis C

1 reference

12 December 2020

Single donor platelets: can we afford to use them? Can we afford not to use them?

1 reference

12 December 2020

Cost-effectiveness of 24 or 48 weeks of interferon alpha-2b alone or with ribavirin as initial treatment of chronic hepatitis C. International Hepatitis Interventional Therapy Group.

1 reference

12 December 2020

[Transfusion-induced virus infections: how great is the risk?]

1 reference

12 December 2020

The UK blood transfusion service: over a (patent) barrel?

1 reference

12 December 2020

Cost-effectiveness of preoperative autologous donation in coronary artery bypass grafting

1 reference

12 December 2020

Bacterial contamination of platelet concentrates: incidence, significance, and prevention

1 reference

12 December 2020

Natural history and disease manifestations of hepatitis C infection.

1 reference

12 December 2020

Rational use of blood products

1 reference

12 December 2020

Economic methods for measuring the quality of life associated with HIV infection.

1 reference

12 December 2020

Cost-effectiveness of expanded human immunodeficiency virus-testing protocols for donated blood

1 reference

12 December 2020

Pharmaco-economics of blood transfusion safety: review of the available evidence

1 reference

12 December 2020

Treatment of hepatitis C.

1 reference

12 December 2020

The care of HIV-infected adults in the United States. HIV Cost and Services Utilization Study Consortium.

1 reference

12 December 2020

Evaluation of an automated culture system for detecting bacterial contamination of platelets: an analysis with 15 contaminating organisms

1 reference

12 December 2020

The natural history of hepatitis C viral infection.

1 reference

12 December 2020

Newly diagnosed hepatitis C. Lack of symptoms doesn't mean lack of progression

1 reference

12 December 2020

A convenient approximation of life expectancy (the "DEALE"). I. Validation of the method.

1 reference

12 December 2020

Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population

1 reference

12 December 2020

Low incidence of second neoplasms among children diagnosed with acute lymphoblastic leukemia after 1983.

1 reference

12 December 2020

The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations

1 reference

12 December 2020

The rationale for pathogen inactivation treatment of platelet components--introduction

1 reference

12 December 2020

Willingness to pay for a quality-adjusted life year: in search of a standard

1 reference

12 December 2020

Prevention of transfusion-associated graft-versus-host disease by photochemical treatment

1 reference

12 December 2020

Evaluation of a reporting system for bacterial contamination of blood components in the United States

1 reference

12 December 2020

A convenient approximation of life expectancy (the "DEALE"). II. Use in medical decision-making.

1 reference

12 December 2020

Hepatitis B virus transmission by blood donation negative for hepatitis B surface antigen, antibody to HBsAg, antibody to hepatitis B core antigen and HBV DNA.

1 reference

12 December 2020

Photochemical inactivation of bacteria and HIV in buffy-coat-derived platelet concentrates under conditions that preserve in vitro platelet function

1 reference

12 December 2020

The cost effectiveness of preoperative autologous blood donations

1 reference

12 December 2020

Transfusion-transmitted bacterial infection in the United States, 1998 through 2000

1 reference

12 December 2020

Physicians' preference values for hepatitis C health states and antiviral therapy: a survey

1 reference

12 December 2020

Determinants of transfusion-associated bacterial contamination: results of the French BACTHEM Case-Control Study

1 reference

12 December 2020

Cost-effectiveness of transfusing virus-inactivated plasma instead of standard plasma

1 reference

12 December 2020

Why is there such difficulty in defining the natural history of hepatitis C?

1 reference

12 December 2020

Cost-utility analyses of clinical preventive services: published ratios, 1976-1997.

1 reference

12 December 2020

Occupational exposure to human immunodeficiency virus and hepatitis B virus: a comparative analysis of risk

1 reference

12 December 2020

The future use of pathogen-inactivated platelet concentrates

1 reference

12 December 2020

Platelet transfusions: utilization and associated costs in a tertiary care hospital

1 reference

12 December 2020

10.1016/S0149-2918(03)80288-6

Identifiers

DOI

1 reference

26 November 2017

1 reference